NasdaqGS - Delayed Quote USD

IGM Biosciences, Inc. (IGMS)

9.40 +1.75 (+22.88%)
At close: April 26 at 4:00 PM EDT
9.41 +0.01 (+0.11%)
After hours: April 26 at 6:26 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,130.00
2,130.00
1,069.00
--
--
Operating Expense
265,591.00
265,591.00
229,025.00
165,323.00
83,280.00
Operating Income
-263,461.00
-263,461.00
-227,956.00
-165,323.00
-83,280.00
Net Non Operating Interest Income Expense
17,743.00
17,743.00
7,035.00
159.00
1,925.00
Other Income Expense
-20.00
-20.00
-181.00
159.00
1,925.00
Pretax Income
-245,738.00
-245,738.00
-221,102.00
-165,164.00
-81,355.00
Tax Provision
678.00
678.00
--
--
--
Net Income Common Stockholders
-246,416.00
-246,416.00
-221,102.00
-165,164.00
-81,355.00
Diluted NI Available to Com Stockholders
-246,416.00
-246,416.00
-221,102.00
-165,164.00
-81,355.00
Basic EPS
-4.71
--
-5.32
-4.93
-2.65
Diluted EPS
-4.71
--
-5.32
-4.93
-2.65
Basic Average Shares
52,311.96
--
41,543.95
33,479.78
30,748.28
Diluted Average Shares
52,311.96
--
41,543.95
33,479.78
30,748.28
Total Operating Income as Reported
-263,461.00
-263,461.00
-227,956.00
-165,323.00
-83,280.00
Total Expenses
265,591.00
265,591.00
229,025.00
165,323.00
83,280.00
Net Income from Continuing & Discontinued Operation
-246,416.00
-246,416.00
-221,102.00
-165,164.00
-81,355.00
Normalized Income
-246,416.00
-246,416.00
-221,102.00
-165,164.00
-81,355.00
Interest Income
17,743.00
17,743.00
7,035.00
159.00
1,925.00
Net Interest Income
17,743.00
17,743.00
7,035.00
159.00
1,925.00
EBIT
-263,461.00
-263,461.00
-227,956.00
-165,323.00
-83,280.00
EBITDA
-255,184.00
-255,184.00
-221,881.00
-160,839.00
-82,255.00
Reconciled Depreciation
8,277.00
8,277.00
6,075.00
4,484.00
1,025.00
Net Income from Continuing Operation Net Minority Interest
-246,416.00
-246,416.00
-221,102.00
-165,164.00
-81,355.00
Normalized EBITDA
-255,184.00
-255,184.00
-221,881.00
-160,839.00
-82,255.00
Tax Rate for Calcs
0.00
0.00
--
--
--
12/31/2020 - 9/18/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CGEM Cullinan Therapeutics, Inc.
25.30
+31.43%
 
MRUS Merus N.V.
45.04
+0.24%
 
ALXO ALX Oncology Holdings Inc.
16.86
-0.06%
 
KYTX Kyverna Therapeutics, Inc.
15.47
-2.95%
 
SYRE Spyre Therapeutics, Inc.
33.56
+3.36%
 
YMAB Y-mAbs Therapeutics, Inc.
14.71
-0.88%
 
LEGN Legend Biotech Corporation
45.30
+1.98%
 
PRLD Prelude Therapeutics Incorporated
4.0700
+0.74%
 
ACRV Acrivon Therapeutics, Inc.
8.46
-0.12%
 
RCUS Arcus Biosciences, Inc.
15.55
+5.57%